A PROSPECTIVE OBSERVATIONAL STUDY ON EFFECTS OF HEPATOPROTECTIVE AGENTS IN ALCOHOLIC LIVER DISEASE AT A TERTIARY CARE HOSPITAL by Ahmed, Hanan Fatima et al.
Ahmed et al                                                                                                              Journal of Drug Delivery & Therapeutics. 2018; 8(1):7-12                       
ISSN: 2250-1177                                                                               [7]                                                                              CODEN (USA): JDDTAO 
Available online on 15.01.2018 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-17, publisher and licensee JDDT, This is an Open Access article which permits unrestricted non-
commercial use, provided the original work is properly cited 
Open  Access                                                                                                                     Research Article 
A PROSPECTIVE OBSERVATIONAL STUDY ON EFFECTS OF 
HEPATOPROTECTIVE AGENTS IN ALCOHOLIC LIVER DISEASE 
















Department of Pharmacy Practice (PharmD), MESCO College of Pharmacy, Osmania University, Hyderabad, T.S. India 
2
Department of Clinical Pharmacology, Osmania General Hospital, Hyderabad, T.S. India 
 
ABSTRACT 
Drug utilization evaluation of hepatoprotective drugs is important in view of the spectrum of effect and associated risks with their 
therapy. The study was designed to evaluate the effects and adverse effects of hepatoprotective agents. A prospective, observational 
study was carried out for a period of 6 months at Osmania General Hospital (a tertiary care hospital). 120 patients were evaluated 
receiving corticosteroids, pentoxifylline, ursodeoxycholic acid for observing a trend in hepatic parameters and its outcomes. 
Ursodeoxycholic acid (81.66%) was the most commonly prescribed drug in almost all cases of alcoholic liver diseases followed by 
pentoxifylline (10%) in hepatorenal syndrome and then prednisolone (8.33%) in fatty liver. 67 cases were reported to have the 
significant drop in liver transaminases and bilirubin levels. Ursodeoxycholic acid resulted in a drop of 25% serum bilirubin and 35% 
drop in serum ALT (alanine transaminase) and 33% drop in serum AST (aspartate transaminase) in patients in a time gap of 1 week. 
Among 120 cases 94 were males (78.05%) and 26 females (21.04%) and maximum patients with alcoholic liver disease belonged to 
age group of 30-40 years (27.6%). Ursodeoxycholic acid (300 mg once daily) is used as an off-label drug for all types of alcoholic 
liver disease and also for viral hepatitis. Though Ursodeoxycholic acid showed a significant drop in liver transaminases and serum 
bilirubin levels in cirrhotic patients a better alternative lie in liver transplantation as long as they remain abstinent from alcohol.  
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Drug utilization evaluation of hepatoprotective drugs is 
important in view of the spectrum of effect and 
associated risks with their therapy. The study was 
designed to evaluate the effects and adverse effects of 
hepatoprotective agents. Drug use indicators are 
intended to determine definite aspects of health 
providers & drug use in a hospital or health center. 
Indicators will give data to health care managers 
regarding drug use, prescribing habits & important 
views of patient care.
1
 The drugs capable of preventing 
alcohol-related injury or limiting and repairing damage 
already sustained might play an important role in the 
management of alcoholic patients. A number of so-
called hepatoprotective agents are available and are 
extensively used, however the evidence that their use 
without abstinence conferring any benefits is poor 
2
. 
The standard therapy for treating alcoholic hepatitis is 
corticosteroids.
3
 Corticosteroids act by reducing 
inflammatory cytokines such as tumor necrosis factor-α 
(TNF-α), intercellular adhesion molecule 1, interleukin 
(IL)-6 and IL-8.
4, 5
 Inflammation is a major component 
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of AH pathogenesis. Prednisolone is given orally in a 
dose of 40-60 mg/d for a total duration of 4 weeks. The 
treatment is then tapered over next 2-3 week. Being the 
first line agent in alcoholic hepatitis prednisolone was 
not prescribed due to increased susceptibility to 




For patients who have contraindications to steroids, the 
second option for treatment is oral pentoxifylline (PTX), 
a phosphodiesterase and a possible TNF-α inhibitor. 
Pentoxifylline is given orally at a dose of 400 mg three 
times a day for a total duration of 28 days. The exact 
mechanism of action of pentoxifylline is not entirely 
clear. Neutralization of TNF-α by pentoxifylline may 
explain the protective effect of this drug on HRS 
(hepatorenal syndrome).
7 
Ursodeoxycholic acid (UDCA) is a physiologic 
hydrophilic dihydroxy bile acid which was approved by 
FDA for cholesterol gallstone dissolution and primary 
biliary cirrhosis.
8-11
 UDCA does not affect long-term 
survival or transplant-free survival but achieves a 25% 
drop in serum bilirubin a 35 % drop in serum alanine 
transaminase, 33% in aspartate transaminase.
12-15
 Hence, 
it is used as an off-label treatment for treating alcoholic 
liver disease. The study was carried out to evaluate 
utilization of hepatoprotective agents in subjects affected 
with the alcoholic liver disease. 
MATERIALS AND METHODS 
Study design, site and ethical approval    
The present prospective, observational study was carried 
out at Osmania General Hospital, a tertiary care teaching 
hospital in Hyderabad, India for a period of 6 months 
(January 2016 to June 2016). Before initiating the study, 
the study was approved by Institutional Ethics 
Committee (IEC) bearing No. MCP/IEC/PD/PR/09. 
Study criteria 
The subjects included were patients of either sex above 
18 years of age undergoing treatment in general 
medicine department in the hospital who were diagnosed 
with the alcoholic liver disease. The patients under 18 
years age group, pregnant and lactating women, patients 
with drug-induced liver disease and liver carcinoma and 
with comorbid cardiac diseases were excluded from our 
study to have a better outcome of the study. 
Data collection 
Patients who corroborate the study protocol criteria were 
included and the required data were collected from the 
patient case sheet. The patient’s physiological 
parameters were monitored timely and were recorded in 
a pre-designed form which included data like ALT, 
AST, and serum bilirubin. Changes in AST, ALT, and 
serum bilirubin were considered in patients being treated 
with ursodeoxycholic acid. A graph was plotted with 
AST, ALT and serum bilirubin at the time of admission 
and then after being treated with ursodeoxycholic acid. 
The CAGE (Concern/Cut-down, Anger, Guilt, and Eye-




During the present study medication chart of patient was 
also observed for any drug-drug interaction relating the 
hepatoprotective drug used and any adverse drug 
reactions felt by the patients on hepatoprotective 
treatment. 
Statistical analysis 
Data analysis was done by using the software Prism 0.5. 
Differences between means of groups were compared 
using student t-test (paired t-test). The results were 
expressed in terms of number and percentage. 
RESULTS 
Demographic details of subjects  
A total of 120 subjects were assessed for the 6 months 
study period. The demographic details of study 
participants are depicted in figure 1. The result shows 
that the incidence of fatty liver was highest in the age 
group of 30-40 (5.83%) and alcoholic hepatitis (3.63%) 
in the age group of 40-50 and cirrhosis (18.33%) in the 
age group of 40-50 and viral hepatitis (5.83%) in the age 
group of 20-30. 
                   
                       
Figure 1: Distribution of subjects based on age group. 
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Distribution of disease based on gender 
 
Figure 2: Distribution of subjects based upon age 
groups. 
The total number of male patients was more than female 
in our study i.e. 78.33% and 21.66% respectively (figure 
2). 
Duration of intake of alcohol and its effect on gender 
The result shows that women are more prone to develop 
alcoholic liver and are more likely to progress to liver 
fibrosis earlier than men even at smaller amounts of 
consumption. The mean duration of intake of alcohol 
among women was observed within 1-5 years and in the 
case of men, it was observed to be within 10-15 years. 
The data is shown in figure 3. 
 
                  
Figure 3: Duration of intake of alcohol and its effect on gender 
 
Differentiating causes of liver damage based on 
AST/ALT ratio  
The highest number of cases was of cirrhosis (55.83%) 
depending on AST/ALT ratio followed by Alcoholic 
hepatitis (33.33%) and viral hepatitis (10.83%). This 
data is shown in table 1. 
Table 1: Differentiating causes of liver damage based on 
AST/ALT ratio. 
Disease condition AST/ALT ratio % of cases 
viral hepatitis 0-1 10.83 
Cirrhosis 1-2 55.83 
alcoholic hepatitis >2 33.33 
                
Hepatoprotective drugs utilization 
In this study ursodeoxycholic acid (81.66%) was the 
most commonly prescribed drug in almost all cases of 
alcoholic liver diseases followed by pentoxifylline 
(10%) in hepatorenal syndrome and then prednisolone 
(8.33%) in fatty liver. The data is reported in figure 4. 
 
Figure 4: Hepatoprotective drugs utilization 
Effect of ursodeoxycholic acid on Aspartate 
Transaminase, alanine transaminase, and serum 
bilirubin 
The study showed drop of 25 % serum bilirubin and 
35% drop in serum alanine transaminase and 33% drop 
in aspartate transaminase in patients receiving 
ursodeoxycholic acid in a time gap of 1 week. This is 
reported in figure 5, figure 6 and figure 7 for AST, ALT 
and serum bilirubin respectively. 
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Figure 5: Effect of ursodeoxycholic acid on Aspartate Transaminase 
 
 
Figure 6: Effect of ursodeoxycholic acid on alanine transaminase 
 
 
Figure 7: Effect of Ursodeoxycholic acid on serum Bilirubin 
 
Adverse effects 
A total of 120 cases of the alcoholic liver disease were 
recorded out of which 32 cases were identified with 
adverse effects. Ursodeoxycholic acid caused watery 
diarrhea in 20.83% of cases and pruritus in 4.16% of 
cases, pentoxifylline caused dizziness in 1.66% of cases. 
The data is recorded in table 2. 
 
 
Table 2: Adverse effects 
% of  Cases Adverse Effects Drug Related 
20.83 Watery Diarrhea Ursodeoxycholic Acid 
1.66 Dizziness Pentoxifylline 
4.16 Pruritis Ursodeoxycholic Acid 
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Statistical analysis 
Table 3: Analysis of alanine transaminase values before 
and after administration of Ursodeoxycholic Aci 
Table Analyzed Paired t test data 
Column B After 
vs. vs. 
Column A Before 
Paired t test  
P value <0.0001 




Table 4: Analysis of aspartate transaminase values 
before and after administration of Ursodeoxycholic Acid 
Table Analyzed Paired t test data 
Column B After 
vs. vs. 
Column A Before 
Paired t test 
P value <0.0001 




Table 5: Analysis of bilirubin values before and after 
administration of Ursodeoxycholic Acid. 
Table Analyzed Paired t test data 
Column B After 
vs. vs. 
Column A Before 
Paired t test 
P value <0.0001 





In developing countries like India, the alcoholic liver 
disease remains the most common cause of morbidity 
and mortality.
 17
 Alcoholic liver diseases occur in a 
majority of subjects who drink large quantities of 
ethanol on a daily basis for many years. The diagnostic 
criteria for alcoholic hepatitis are based entirely on the 
appropriate alcohol intake history, fever, jaundice, 
ascites, elevated WBC (white blood cells), AST<400 
IU/mL and elevated AST: ALT ratio.
18
 Liver biopsy 
may help confirm the diagnosis but is not required. 
Abstinence remains the cornerstone of management of 
all forms of the alcoholic liver disease. Prednisolone 40 
mg/day for 28 days is the most widely opted treatment 
option; however it is contraindicated in patients with 
recent upper gastrointestinal bleeding, elevated 
creatinine or uncontrolled infection. Pentoxifylline 400 
mg thrice daily for 28 days is an alternate treatment 
option. A potential benefit of pentoxifylline treatment is 
that it can be used in patients with infection and in 
patients with renal insufficiency. Consequently, liver 
transplantation remains an ultimate option for selected 
patients with liver failure due to chronic alcoholic liver 
damage. 
A prospective, observational, noninvasive study was 
carried out at the department of General Medicine, 
Osmania General Hospital, a tertiary care teaching 
hospital, for a period of 6 months. During the study 
period, a total of 120 cases of the alcoholic liver disease 
were recorded from January 2016 to June 2016, out of 
which 67 cases were reported to have a significant drop 
in liver transaminases and bilirubin levels. Women are 
more prone to develop alcoholic liver and are more 
likely to progress to liver fibrosis earlier than men even 
at smaller amounts of consumption. Mean duration of 
intake of alcohol among women was observed within 1-
5 years and in case of men it was observed to be within 
10-15 years, which was similar to that of studies 
reported in literature by Bernadt et al. 1982,
19
 Sato et al. 
2001, 
20
 Wechsler and Austin et al. 1998,
21
 and Barrio 
and Rodriguez et al. 2004.
22 
Gender specific 
susceptibility to alcohol hepatotoxicity has been 
attributed to women having lower gastric levels of 
alcohol dehydrogenase, leading to slower first-pass 
metabolism of alcohol, higher gut permeability, causing 
higher endotoxin levels after alcohol ingestion that in 
turn lead to more aggressive oxidative stress and 
inflammation, larger body fat content, resulting in a 
lower volume of distribution for alcohol. 
The AST: ALT ratio was useful in differentiating the 
cause of liver damage, the AST: ALT ratio of 2 or more 
may be associated with alcoholic hepatitis and a ratio of 
>1and <2 is suggestive of cirrhosis and less than 1 is 
associated with viral hepatitis. This is in accordance with 
the study of Vuittonet and Kenna et al. 2014.
23
 Many 
patients were contraindicated to corticosteroid therapy 
such as active infection and are more prone to variceal 
bleeding hence patients were switched to pentoxifylline 
which is in accordance with studies reported by 
Halegoua-De Marzio and Fenkel 2013.
3 
Ursodeoxycholic acid resulted in a drop of 25 % serum 
bilirubin and 35% drop in serum alanine transaminase 
and 33% drop in aspartate transaminase in patients in a 
time gap of 1 week after administration of the drug 
which is in accordance with the study reported by Kotb 
2012.
24
 Ursodeoxycholic acid toxicity included pruritis, 
severe watery diarrhea which is seen in the study of 
Kotb 2012.
24
 The drawback of glucocorticoid use in 
patients with alcoholic hepatitis is increased 
susceptibility to infections is according to the study by 
Thursz et al. (2015).
25 
CONCLUSION 
The present study has demonstrated the effects of 
hepatoprotective agents on physiological parameters in 
alcoholic liver disease patients.  The optimal 
management of alcoholic liver disease begins with 
therapeutic lifestyle changes, in which abstinence or 
dramatic reduction in alcohol use is crucial. Abstinence 
has a profound beneficial effect on survival at all stages 
of the disease.  Corticosteroid being the first line agent 
in alcoholic liver disease was not prescribed due to 
increased susceptibility to infections and it also has a 
tendency to increase variceal bleeding. Pentoxifylline is 
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considered to be a better alternative to glucocorticoid 
therapy particularly in patients who are at risk for 
hepatorenal syndrome (worsening creatinine, infection, 
hyponatremia). Ursodeoxycholic acid is used as an off-
label drug for all type of alcoholic liver diseases and also 
for viral hepatitis. Ursodeoxycholic acid resulted in a 
drop of 25 % serum bilirubin and 35% drop in serum 
alanine transaminase and 33% drop in aspartate 
transaminase in patients in a time gap of 1 week. 
Management of alcoholic liver disease relies on 
abstaining from alcohol along with treating alcohol 
withdrawal, providing nutritional support and managing 
cirrhosis-related complications.  
The pharmacist is the key person for better management 
of therapy based on stage and condition of the patient 
and to manage any unwanted effects. Sincere efforts has 
been taken to educate the patients on ill effects 
concerned with the usage of alcohol on health, family, 
social well-being and on community and to minimize 
any adverse effects (at least to some extent) by our 
dissertation. 
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